PHAS Key Statistics, Chart & Performance
The current stock price of PHAS is 0.0701 USD. In the past month the price decreased by -61.78%. In the past year, price decreased by -98.16%.
PHAS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.7 | 412.54B | ||
| AMGN | AMGEN INC | 15.62 | 183.97B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.89 | 122.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 18.05 | 85.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 828.43 | 55.82B | ||
| INSM | INSMED INC | N/A | 37.54B | ||
| NTRA | NATERA INC | N/A | 35.11B | ||
| BIIB | BIOGEN INC | 11.17 | 27.42B | ||
| INCY | INCYTE CORP | 17.22 | 21.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 21.69B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.86B |
Related stock screener links
About PHAS
Company Profile
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2018-10-18. The Company’s product pipeline includes Bentracimab (PB2452), PB6440 (for treatment-resistant Hypertension), pemziviptadil (PB1046), GLP2-ELP and CNP-ELP. The firm conducting REVERSE-IT, its pivotal Phase III clinical trial of bentracimab. PB2452 is a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor in the event of major bleeding. PB6440 is an oral selective aldosterone synthase inhibitor for treatment of resistant hypertension. Pemziviptadil (PB1046), is a novel, subcutaneously-injected VIP analogue, which is a recombinant fusion protein composed of VIP and its proprietary ELP technology. ELP technology platform is a growth engine for additional medicines for cardiovascular diseases.
Company Info
PHASEBIO PHARMACEUTICALS INC
1 Great Valley Pkwy Ste 30
Malvern PENNSYLVANIA 19355 US
CEO: Jonathan P. Mow
Employees: 60
Phone: 16109816500.0
PHASEBIO PHARMACEUTICALS INC / PHAS FAQ
What does PHAS do?
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2018-10-18. The Company’s product pipeline includes Bentracimab (PB2452), PB6440 (for treatment-resistant Hypertension), pemziviptadil (PB1046), GLP2-ELP and CNP-ELP. The firm conducting REVERSE-IT, its pivotal Phase III clinical trial of bentracimab. PB2452 is a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor in the event of major bleeding. PB6440 is an oral selective aldosterone synthase inhibitor for treatment of resistant hypertension. Pemziviptadil (PB1046), is a novel, subcutaneously-injected VIP analogue, which is a recombinant fusion protein composed of VIP and its proprietary ELP technology. ELP technology platform is a growth engine for additional medicines for cardiovascular diseases.
Can you provide the latest stock price for PHASEBIO PHARMACEUTICALS INC?
The current stock price of PHAS is 0.0701 USD. The price decreased by -26.21% in the last trading session.
Does PHAS stock pay dividends?
PHAS does not pay a dividend.
What is the ChartMill rating of PHASEBIO PHARMACEUTICALS INC stock?
PHAS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is PHAS stock listed?
PHAS stock is listed on the Nasdaq exchange.
Is PHASEBIO PHARMACEUTICALS INC (PHAS) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PHAS.
Can you provide the market cap for PHASEBIO PHARMACEUTICALS INC?
PHASEBIO PHARMACEUTICALS INC (PHAS) has a market capitalization of 3.50M USD. This makes PHAS a Nano Cap stock.
PHAS Technical Analysis
PHAS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHAS. PHAS has a bad profitability rating. Also its financial health evaluation is rather negative.
PHAS Financial Highlights
Over the last trailing twelve months PHAS reported a non-GAAP Earnings per Share(EPS) of -2.13. The EPS increased by 36.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -12572.13% | ||
| ROA | -463.95% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
PHAS Forecast & Estimates
7 analysts have analysed PHAS and the average price target is 1.02 USD. This implies a price increase of 1355.06% is expected in the next year compared to the current price of 0.0701.
For the next year, analysts expect an EPS growth of 59.21% and a revenue growth -64.49% for PHAS